<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> is commonly associated with elevated plasma free fatty acid (FFA) levels, as well as with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo>, two important <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>What causes <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> in <z:hpo ids='HP_0001513'>obesity</z:hpo> remains uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we have tested the hypothesis that FFAs are the link between <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>/<z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and that, therefore, lowering of chronically elevated plasma FFA levels would improve <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>/<z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance in <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic and diabetic subjects </plain></SENT>
<SENT sid="3" pm="."><plain>Acipimox (250 mg), a long-acting antilipolytic drug, or placebo was given overnight (at 7:00 P.M., 1:00 A.M., 7:00 A.M.) to 9 lean control subjects, 13 <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic subjects, 10 <z:mp ids='MP_0001261'>obese</z:mp> subjects with <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, and 11 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Euglycemic-hyperinsulinemic clamps and oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests (75 g) were performed on separate mornings after overnight Acipimox or placebo treatment </plain></SENT>
<SENT sid="5" pm="."><plain>In the three <z:mp ids='MP_0001261'>obese</z:mp> study groups, Acipimox lowered fasting levels of plasma FFAs (by 60-70%) and plasma insulin (by approximately 50%) </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake during euglycemic-hyperinsulinemic clamping was more than twofold higher after Acipimox than after placebo </plain></SENT>
<SENT sid="7" pm="."><plain>Areas under the <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin curves during oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance testing were both approximately 30% lower after Acipimox administration than after placebo </plain></SENT>
<SENT sid="8" pm="."><plain>We conclude that lowering of elevated plasma FFA levels can reduce <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>/<z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and improve oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance in lean and <z:mp ids='MP_0001261'>obese</z:mp> nondiabetic subjects and in <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>